| Literature DB >> 31015851 |
Li Tan1,2, Liling Zeng1, Ning Wang3, Meijun Deng1, Yinshi Chen1, Tianyi Ma1, Luhan Zhang1, Zhenhua Xu2.
Abstract
Traumatic brain injury (TBI) has become an economic and social burden for patients and their families. While acupuncture is an effective tool for promoting recovery of disorder of consciousness (DOC) following TBI, there have been no comprehensive meta-analyses and/or systematic reviews addressing this topic. The present systematic review and meta-analysis aimed to assess the therapeutic efficacy of acupuncture for DOC after TBI. All randomized controlled trials (RCTs) incorporating acupuncture, or acupuncture combined with other interventions for DOC after TBI, were included and assessed by two independent investigators. Six outcome indicators were assessed: Glasgow Coma Scale (GCS); Glasgow Outcome Scale (GOS); mortality; efficacy rate; activities of daily living (ADL); and functional comprehensive assessment. Direct comparisons were performed using RevMan 5.3.0 software, with results presented as mean difference (MD) for continuous outcomes and relative risk (RR) for binary outcomes. A total of 3511 patients from 49 trials were included. Pooled analyses indicated that acupuncture may have a superior effect on GCS score (MD=2.03, 95% CI :1.92 2.43, Z=16.54, and P<0.00001); GOS score (RR=1.23, 95%CI: 1.18 1.35, Z=6.65, and P<0.00001); efficacy rate (RR=1.48, 95%CI: 1.40 1.56, Z=13.49, and P<0.00001); ADL (MD=9.20, 95% CI:8.19 10.21, Z=17.84, and P<0.00001); and mortality (RR=0.50, 95% CI:0.38 0.67, Z=4.70, and P<0.00001). The results demonstrated that the acupuncture group fared better than the control group in the treatment of DOC after TBI. However, studies were generally of poor quality, and publication bias favoring positive studies was obvious. Therefore, rigorous evaluation standards and well-designed studies are necessary in future studies.Entities:
Year: 2019 PMID: 31015851 PMCID: PMC6444240 DOI: 10.1155/2019/5190515
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The screening flow diagram.
The basic characteristic of the included studies.
| Studies | Simple Size | Mean age | Intervention | GCS before treatment (T/C) | TBI's Degree | Duration of Treatment | Outcome measure |
|---|---|---|---|---|---|---|---|
| Fu 2009 | 16(12/4)/16(14/3) | 41.8±18.5/36.8±18.5 | EA/BT | 4.06±1.06/3.87±1.02 | S | 30 D | GCS |
| He 2012 | 30/20 | NR | EA/BT | NR | S | 1 M | GOS |
| Yu 2010 | 34/34 | NR | A/BT | 5.60±2.25/5.81±2.23 | S | 1 M | GCS |
| Yu 2012 | 30/30 | 33.38±12.65 | A/BT | 5.63±1.69/5.80±1.79 | S | 1 M | GCS |
| Feng 2005 | 44(29/15)/40(29/15) | 39±15/36±13 | A/BT | (3-5/9,6-8/35)/(3-5/3,6-8/32) | S | 1 M | GCS/GOS |
| Liu 2015 | 43/42 | NR | A/BT | NR | S | 1 M | GOS |
| Liu 2010 | 15(9/6)/14(9/6) | 32.6±15.3/31.9±15.8 | EA/BT | (5/3,6/4,7/3,8/5)/(5/3,6/3,7/4,8/4) | S | U | GOS |
| Liu 2016 | 43(30/12)/42(29/14) | 38.61±4.65/36.92±4.87 | A/BT | 3-5/22,6-8/35,9-11/17,12-15/11 | S/Mo/Mi | 30 D | GOS |
| Liu 2006 | 50(34/16)/50(32/18) | NR | EA/BT | (3-5/12,6-8/38)/(3-5/11,6-8/39) | S | 30 D | GOS |
| Liu et.al. 2006 | 60(44/16)/60(42/18) | 32.5/32 | A+HO+LII/BT | (8/19,7/36,≤6/5)/(8/18,7/36,≤6/6) | S | 30 D | GCS |
| Lu 2015 | 37(22/15)/37(22/15) | 39.6±1.5/30.21±1.8 | EA/BT | NR | S | 30 D | GOS |
| Gu 2010 | 61(42/19)/61(41/20) | 45±12.11/43.1±11.12 | A+TCM/BT | (3-5/23,6-8/38)/(3-5/24,6-8/37) | S | 1 W | GOS |
| Lv 2013 | 43(23/20)/42(25/17) | 42.5±12.7/41.7±13.2 | EA/BT | 3.9±1.1/4.01±1.06 | S | 30 D | GCS/GOS |
| Tang 2016 | 15(11/4)/15(11/3) | 49.53±15.73/52.14±11.36 | EA/BT | 5.80±1.47/5.57±1.22 | S | 4 W | GCS/GOS |
| Lou 2013 | 25/25 | NR | A+HO/BT | NR | S | U | GOS |
| Sun 2009 | 30(22/8)/30(20/10) | 45.2/39.8 | A/BT | (3-5/9,6-8/21)/(3-5/8,6-8/22) | S | 2 M | GOS |
| Song 2007 | 30/20 | NR | EA/BT | NR | S | 1 M | GOS |
| Zhang 2013 | 30(19/11)/30(21/9) | 37.1±9.1/37.2±10.1 | EA/BT | (3-5/13,6-8/17)/(3-5/12,6-8/18) | S | 1 M | GOS |
| Zhang 2011 | 22(19/3)/20(14/6) | 43.50±1.27/46.25±1.31 | A/BT | 6.41±1.47/6.45±1.47 | S | 30 D | GCS |
| Peng 2010 | 29(20/9)/27(20/7) | 39.1±12.2/40.2±9.8 | EA/BT | 5.08±1.47/5.10±2.11 | S | 1 M | GOS |
| Cheng 2016 | 28/29 | NR | EA/BT | 5.42±1.29/5.68±1.54 | S | U | GCS |
| Li 2003 | 40(29/11)/40(27/13) | 39±15/36±14 | A+TCM/BT | (3-5/9,6-8/31)/(3-5/8,6-8/32) | S | 1 M | GOS |
| Li 2010 | 16(12/4)/14(10/4) | 45.6/46.4 | A+TCM/BT | (3-5/4,6-8/12)/(3-5/4,6-8/10) | S | 1 M | GOS |
| Yang 2011 | 15(11/4)/15(10/5) | 37.4/35.1 | A+HO/BT | 5.7/5.9 | S | 30 D | GCS |
| Yang 2007 | 20(11/9)/20(12/8) | 40.25±0.36/42.06±0.28 | EA/BT | 6.5±1.471/6.6±1.04 | S | 7 D | GCS |
| Yang 2016 | 50/40 | NR | A/BT | NR | S | 60 D | GOS |
| Jiang 2009a | 33(25/8)/30(26/4) | NR | A+HO/BT | NR | S | U | GOS |
| jiang 2009b | 76(53/12)/58(48/10) | 28.1/27.4 | A/BT | 5.3±1.18/5.1±1.21 | S | U | GOS |
| You 2013 | 16(12/4)/15(10/5) | 34.7±9.9/35.2±8.7 | A/BT | 6.2±1.7/5.9±1.4 | S | 4 W | GCS |
| Wang 2012 | 50(42/8)/50(40/10) | NR | A/BT | 4.04±1.06/4.08±1.02 | NR | 1 M | GCS |
| Wang 2013 | 50/50 | NR | EA+HO+TCM/BT | NR | S | 2 W | GOS |
| Wang 2016 | 50(37/13)/50(37/13) | 42.36±16.11/43.10±15.33 | A/BT | 5.90±1.53/5.98±1.60 | S | 3 W | GCS |
| Ge 2014 | 23(13/10)/23(15/8) | 32.06±3.18/31.26±4.25 | EA/BT | NR | S | 1 M | GOS |
| Xie 2016 | 32(24/8)/32(25/7) | 39.5/36.9 | A/BT | 4.92±1.17/4.81±1.55 | S | 1 M | GCS |
| Guo 2016 | 30(18/12)/30(20/10) | 35.2±8.43/33.7±7.56 | EA/BT | 6.53±1.18/6.87±7.56 | S | 30 D | GCS |
| Chen 2013 | 39(25/14)/38(26/12) | 31.47±3.88/31.52±3.82 | A+HO/BT | NR | S | U | GOS |
| Chen 2011 | 36/34 | NR | A+HO/BT | NR | S | 1 M | GOS |
| Chen 2006 | 54(36/18)/51(37/14) | 34±11/36±112 | A+TCM/BT | (3-5/15,6-8/39)/(3-5/14,6-8/37) | S | 8 W | GCS/GOS |
| Chen 2009 | 46(38/8)/46(35/11) | 47±2.13/47±2.37 | EA/BT | 4.03±1.05/4.07±1.02 | S/Mo | U | GCS |
| Lu 2014 | 20(12/8)/20(11/9) | 34±116/33±16 | A/BT | (5/6,6/7,7/3,8/4)/(5/5,6/6,7/4,8/5) | S | 30 D | GOS |
| Tu 2010 | 51(35/16)/51(37/14) | 42.5±11.4/41.1±11.2 | A/BT | (3-5/16,6-8/35)/(3-5/17,6-8/34) | S | 30 D | GOS |
| Yan 2018 | 50(32/18)/50(30/20) | 35.2±11.8/34.5±10.3 | EA/BT | 4.6±1.15/4.5±1.44 | S | 1 M | GCS |
| Xue 2017 | 36(25/13)/38(24/12) | 38.15±5.26/39.75±6.18 | A+TCM/BT | 5.75±2.26/6.13±2.27 | S/Mo | 8 W | GCS/GOS |
| Xu 2015 | 30(19/12)/30(18/11) | 39.75±17.86/9.06±2.03 | A/BT | 6.0±1.80/5.9±1.70 | S | 14 D | GCS/GOS |
| Xing 2007 | 20/20 | NR | A/BT | 5.9±0.85/5.00±1.17 | S | 4 W | GCS |
| Wang et al 2016 | 39(22/17)/39(21/18) | 53.5±2.4/53.4±2.5 | A+HO/BT | 6.3±1.36/6.4±1.14 | NR | 3 M | GCS |
| Ding 2015 | 40(24/16)/40(22/18) | 35.8±4.3/35.4±4.3 | A+TCM/BT | 5.7±1.06/10.05±1.3 | NR | U | GCS |
| Zhang 2014 | 80(82/44)/46 | 27.7 | A+TCM/BT | NR | S | 2 M | GOS |
| Tian 2012 | 58(85/31)/58 | 43.5 | A/BT | 8.5±3.01/8.46±3.22 | S/Mo | 14 D | GCS/GOS |
NR: not report; A: acupuncture; EA: electroacupuncture; TCM: traditional Chinese medicine; HO: hyperbaric oxygen; BT: basic treatment; Mi: mild TBI; Mo: moderate TBI; S: severe TBI; M: month; W: week; D: day; U: unclear; GCS: Glasgow Coma Scale; GOS: Glasgow Outcome Scale.
Figure 2The bias of each study.
Figure 3The summary of bias evaluation for the studies.
Results of subgroup analysis of GCS by treatment duration, TBI's degree, and intervention.
| Variables | Numbers of studies | Numbers of patient(T/C) | MD(95%CI) | Heterogeneity(I2) | Z-value |
| |
|---|---|---|---|---|---|---|---|
| Treatment duration | 7d | 1 | 20/20 | 2.20 [1.28, 3.12] | Not applicable | 4.71 |
|
| 14d | 2 | 89/87 | 2.42 [1.56, 3.29] | 0% | 5.48 |
| |
| 3W | 1 | 50/50 | 2.42 [1.29, 3.55] | Not applicable | 4.18 |
| |
| 4W or 30d or 1M | 12 | 358/354 | 2.20 [1.80, 2.59] | 2% | 10.9 |
| |
| 8W | 2 | 91/91 | 2.13 [0.93, 3.33] | 67% | 3.47 |
| |
| 3M | 1 | 39/39 | 3.20 [2.31, 4.09] | Not applicable | 7.07 |
| |
| Unclear | 3 | 144/127 | 1.34 [-0.24, 2.92] | 96% | 2.02 |
| |
| Test for subgroup differences | 85.8% |
| |||||
| TBI's Degree | Severe | 17 | 560/548 | 2.00 [1.49, 2.51] | 68% | 7.69 |
|
| Severe/Moderate | 2 | 91/91 | 2.13 [0.93, 3.33] | 67% | 3.47 |
| |
| Unclear | 3 | 129/129 | 2.03 [-0.06, 4.12] | 95% | 1.91 |
| |
| Test for subgroup differences | 0% | P = 0.98 | |||||
| Intervention | A | 12 | 425/415 | 2.22 [1.47, 2.96] | 83% | 6.07 |
|
| EA | 8 | 248/248 | 2.13 [1.59, 2.68] | 29% | 7.71 |
| |
| A plus TCM | 2 | 85/85 | 0.83 [-0.49, 2.15] | 84% | 1.23 |
| |
| Test for subgroup differences | 43.4% |
| |||||
| Total | 22 | 780/768 | 2.03 [1.54, 2.52] | 78% | 8.17 |
| |
Figure 4Forest plot of GOS.
Figure 5Forest plot of GOS.
Figure 6Forest plot of mortality.
Figure 7Sensitivity analysis.
Figure 8Forest plot of efficacy rate.
Figure 9Funnel plot of efficacy rate.
Figure 10Forest plot of ADL.